Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study-Reference-Cited by-同舟云学术

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

Published:2013-07-17 Issue:10 Volume:27 Page:2032-2039
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Jovanovic J V,Ivey A,Vannucchi A M,Lippert E,Oppliger Leibundgut E,Cassinat B,Pallisgaard N,Maroc N,Hermouet S,Nickless G,Guglielmelli P,van der Reijden B A,Jansen J H,Alpermann T,Schnittger S,Bench A,Tobal K,Wilkins B,Cuthill K,McLornan D,Yeoman K,Akiki S,Bryon J,Jeffries S,Jones A,Percy M J,Schwemmers S,Gruender A,Kelley T W,Reading S,Pancrazzi A,McMullin M F,Pahl H L,Cross N C P,Harrison C N,Prchal J T,Chomienne C,Kiladjian J J,Barbui T,Grimwade D

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2013219.pdf

Reference54 articles.

1. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.

2. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.

3. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.

4. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.

5. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008.

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Superior detection of low-allele burden Janus kinase 2 V617F mutation and monitoring clonal evolution in myeloproliferative neoplasms using chip-based digital PCR;Annals of Hematology;2024-07-24

2. Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges;Frontiers in Immunology;2024-06-13

3. Red cell distribution width and prognosis in myelofibrosis patients treated with ruxolitinib;Annals of Hematology;2024-06-12

4. Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes;Annals of Hematology;2024-05-21

5. Incidence and impact of non-canonical JAK2 p.(Val617Phe) mutations in myeloproliferative neoplasm molecular diagnostics;Journal of Clinical Pathology;2024-05-17